
## Anna Orsola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1496965/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. Journal of Urology, 2007, 178, 1290-1295.	0.2	242
2	Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. Journal of Clinical Oncology, 2015, 33, 643-650.	0.8	165
3	Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer. Urology, 2007, 69, 500-504.	0.5	159
4	Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression. Journal of Urology, 2006, 175, 1679-1683.	0.2	90
5	Cell-specific activation of the HB-EGF and ErbB1 genes by stretch in primary human bladder cells. In Vitro Cellular and Developmental Biology - Animal, 1999, 35, 371-375.	0.7	71
6	Microencapsulation of Leydig Cells: A System for Testosterone Supplementation. Endocrinology, 2003, 144, 4975-4979.	1.4	69
7	Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU International, 2007, 99, 274-280.	1.3	56
8	Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function. Endocrinology, 2002, 143, 4599-4608.	1.4	55
9	Heparin-Binding EGF-Like Growth Factor Is Up-Regulated in the Obstructed Kidney in a Cell- and Region-Specific Manner and Acts to Inhibit Apoptosis. American Journal of Pathology, 2000, 156, 889-898.	1.9	52
10	Controlled release of therapeutic agents: slow delivery and cell encapsulation. World Journal of Urology, 2000, 18, 80-83.	1.2	51
11	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU International, 2007, 99, 812-816.	1.3	50
12	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. Current Oncology Reports, 2011, 13, 216-221.	1.8	48
13	A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 310-319.	3.4	40
14	Alendronate decreases the fracture risk in patients with prostate cancer on androgenâ€deprivation therapy and with severe osteopenia or osteoporosis. BJU International, 2009, 104, 1637-1640.	1.3	36
15	Risk factors for positive findings in patients with highâ€grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmetteâ€Guérin therapy and the decision for a repeat TUR. BJU International, 2010, 105, 202-207.	1.3	36
16	The decision to undergo DNA or protein synthesis is determined by the degree of mechanical deformation in human bladder muscle cells. Urology, 2002, 59, 779-783.	0.5	26
17	Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Current Opinion in Urology, 2013, 23, 466-471.	0.9	19
18	Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303–14. European Urology, 2009, 55, e15-e16.	0.9	15

Anna Orsola

#	Article	IF	CITATIONS
19	Preoperative Prediction of Pathologically Insignificant Prostate Cancer in Radical Prostatectomy Specimens: The Role of Prostate Volume and the Number of Positive Cores. Urologia Internationalis, 2010, 84, 153-158.	0.6	15
20	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anti-Cancer Drugs, 2005, 16, 863-866.	0.7	13
21	Is there a relationship between prostate volume and Gleason score?. BJU International, 2008, 102, 563-565.	1.3	8
22	Growth and stretch response of human exstrophy bladder smooth muscle cells: molecular evidence of normal intrinsic function. BJU International, 2005, 95, 144-148.	1.3	6
23	A novel method for implantation of LNCaP prostate tumor cells under the renal capsule. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 360-362.	0.7	3
24	High-Risk Nonmuscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 227-236.	0.9	3
25	Correspondence Re: "Garat JM, de la Peña E, Caffaratti J, Villavicencio H. Prevention of Vesicoureteral Reflux at the Time of Complete Primary Repair of the Exstrophy-epispadias Complex. Int Urol Nephrol. 2004; 36: 211–2â€. International Urology and Nephrology, 2005, 37, 779-780.	0.6	2
26	Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012;61:378–84. European Urology, 2012, 61, e53-e54.	0.9	2
27	Reply to K. Lu. Journal of Clinical Oncology, 2015, 33, 2716-2717.	0.8	0
28	Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, FernÃindez PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127–136. European Journal of Cancer, 2016, 68, 196-197.	1.3	0